Background: Taxanes [paclitaxel, nab-paclitaxel (Abraxane, Celgene Corp, USA), and docetaxel]-used in the treatment of lung, breast, and head and neck cancers-have been associated with cutaneous adverse effects, including photodermatoses.
Introduction
Taxane-associated cutaneous adverse reactions include photodermatoses [1-3]. We describe a woman with non-small cell lung cancer who developed a dermatitis on sun-exposed areas that progressively worsened with each dose of nab-paclitaxel.
We also review other photodermatoses in patients receiving paclitaxel or nab-paclitaxel and address the treatment options for individuals affected by these drug-associated conditions.
Case report
A 69-year-old woman presented for evaluation with a photodistributed rash on the extensor surfaces of her upper extremities. Her past medical history was significant for stage IV non-small cell lung cancer. She had progressive disease after sequentially receiving prior antineoplastic therapies, Photo recall phenomenon [3] and subacute cutaneous lupus erythematosus [8] [9] [10] However, a recent report has linked subacute cutaneous lupus erythematosus to Kolliphor EL-free nab-paclitaxel. A 62-year-old woman developed erythematous papules and plaques of subacute lupus erythematosus on her sun-exposed arms and chest that appeared after her third infusion with nab-paclitaxel. The lesions completely disappeared after the nab-paclitaxel was withdrawn [7] .
Reports of photosensitivity dermatitis in patients receiving paclitaxel or nab-paclitaxel therapy are uncommon.
However, it is possible that the incidence of these cases is higher than reflected in the literature. We hypothesize that additional affected individuals may not have been recognized or reported since the treatment duration is limited and the dermatoses resolve spontaneously once the agent has been discontinued.
Drug-induced photosensitivity can be phototoxic or photoallergic. Phototoxic dermatoses are common and typically present as a sunburn that appears immediately after moderate exposure to ultraviolet radiation. Conversely, photoallergic reactions are rare and are often characterized by pruritic or eczematous lesions that appear on sun exposed areas of the skin 24-72 hours after minimal sun exposure (Table 1) [11] .
The clinical presentation of our patient's nab-paclitaxelinduced photodermatosis is most consistent with a photoallergic reaction.
The mechanism of pathogenesis for taxane-associated photosensitivity remains to be determined. In some of the patients treated with paclitaxel, aberrations in the biosynthesis of porphyrins have been demonstrated [10, 12] . Whether elevated porphyrins are an essential feature or an epiphenomenon for the development of paclitaxel-related photosensitivity remains to be determined. Our patient declined additional blood and urine studies to evaluate porphyrins after her dermatosis resolved. sitive dermatitis was established. Clobetasol 0.05% cream was applied twice daily and she avoided exposure to the sun.
Most of the erythematous plaques resolved within two weeks.
Triamcinolone 0.1% cream was substituted -initially, twice and then once daily -until the dermatitis completely resolved. The patient was able to continue receiving nabpaclitaxel therapy without recurrence of her symptoms.
Discussion
Taxanes are used in the treatment of lung, breast, ovarian, pancreatic, and head and neck cancers. The first taxane, paclitaxel, was isolated from the bark of the Pacific yew tree However, due to the cost and difficulty of the extraction process and the limited supply of the Pacific yew tree, commercial development of paclitaxel did not begin until 1991 [4, 5] .
Paclitaxel is poorly soluble in water and thus most commercially available preparations once contained the non-ionic solvent Kolliphor EL (BASF, USA, formerly Cremophor EL).
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) was developed in order to reduce or eliminate the risk of hypersensitivity reactions associated with Kolliphor EL-based paclitaxel. Nab-paclitaxel, marketed under the trade name "Abraxane," is an injectable formulation of albumin-linked paclitaxel that can be administered without steroid or antihistamine prophylaxis for hypersensitivity reactions [6] .
Paclitaxel-induced photodermatoses include erythema multiforme, onycholysis, photo recall phenomenon, and subacute cutaneous lupus erythematosus [1]. It is possible that the photodermatosis in some of these patients was associated with Kolliphor EL rather than paclitaxel. To the best of our knowledge, subacute cutaneous lupus erythematosus is the only photosensitivity disorder that has been linked specifically to nab-paclitaxel therapy [7] .
Paclitaxel-induced erythema multiforme on sun-exposed skin has previously been observed. A 40-year-old woman with metastatic breast cancer presented with photodistributed erythema multiforme and onycholysis following treatment with paclitaxel and trastuzumab. Elevated urinary and erythrocyte porphyrins were also observed. The severity of the reaction necessitated withdrawal of paclitaxel therapy. The lesions gradually resolved and the porphyrins normalized following withdrawal of the drug [2] .
Another patient-a 56-year-old woman who was receiving adjuvant weekly paclitaxel for the treatment of intraductal breast carcinoma-developed photodistributed erythema multiforme and onycholysis shortly after brief exposure to sunlight. She developed pruritic and erythematous skin lesions that spread only to sites that were exposed to sunlight:
Treatment of taxane-induced photodermatoses typically involves topical or systemic corticosteroids and photoprotection. Oral antihistamines may also be helpful for some patients [3, 13] . The presence of a photodermatosis is not an absolute contraindication to continuing chemotherapy, especially with strict avoidance of sun exposure. However, withdrawal of the drug may be required if the cutaneous reaction is severe or if the lesions fail to resolve with conservative treatment.
Conclusion
Taxanes are chemotherapeutic agents used in the management of various neoplasms. Paclitaxel and nab-paclitaxel are taxanes that have been associated with photodermatoses, including erythema multiforme, onycholysis, photo recall phenomenon, and subacute cutaneous lupus erythematosus.
The incidence of photodermatoses secondary to paclitaxel or nab-paclitaxel may be higher than the published literature reflects.
The development of symptoms and/or skin lesions on sun-exposed areas in patients receiving these agents should prompt the clinician to evaluate the patient for a drug-related photodermatosis. Evaluation could include serologic tests (to evaluate for lupus erythematosus and porphyria) and tissue biopsy for microscopic examination. 
